Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients with Advanced Urothelial Carcinoma in the EV-301 Trial

Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients with Advanced Urothelial Carcinoma...

The phase 3 EV-301 trial reported enfortumab vedotin prolonged overall survival (OS) among patients who had previously received chemotherapy and checkpoint inhibitors for advanced...

Curated Journal reading List

Advertisement
Advertisement

Expert Interviews